VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone

Stock Information for VolitionRX Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VolitionRX Limited

Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
Volition appoints Dr Andrew Retter as Chief Medical Officer
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
Volition Issues Business Review 2023
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.